Key facts
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Feb 2026.
- Notable investors include CDP Venture Capital (Rome), European Investment Fund, SmartCityLab, B4i - Bocconi for innovation, Cariplo Factory — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for GenoGra
- ·The full record, as it builds
Funding rounds
No funding rounds for GenoGra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GenoGra
Developer of genome analysis technology designed for faster and more accurate interpretation of genetic data. The company offers genome graphs instead of linear models, integrates a proprietary search engine, offers high-performance analysis through hardware acceleration, and includes customizable workflows and user interfaces, enabling researchers and clinicians to reduce tool fragmentation, accelerate processing times, and improve the accuracy and interactivity of large-scale genomic studies.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Employees
- 4
- Website
- genogra.com/
- Ownership
- Privately Held (backing)
GenoGra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenoGra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenoGra in its N-PORT filings yet. We sweep new filings monthly.